GCH1
GCH1 (GTP cyclohydrolase 1, also known as GTPCH1, GCH, DYT5 and DYT5a) is the first and rate-limiting enzyme in tetrahydrobiopterin (BH4) biosynthesis. It converts GTP into 7,8-dihydroneopterin triphosphate and supports nitric oxide and dopamine-related pathways. Browse Assay Genie's current range of GCH1 research reagents below, or read on for the biology behind the target.
GCH1 catalyses the first and rate-limiting step in the biosynthesis of tetrahydrobiopterin (BH4), converting GTP into 7,8-dihydroneopterin triphosphate. BH4 is an essential cofactor for the aromatic amino acid hydroxylases and for the nitric oxide synthases, so GCH1 activity sits upstream of several distinct biochemical pathways. UniProt annotation reports that the protein positively regulates nitric oxide synthesis in human umbilical vein endothelial cells (HUVECs), and that it may be involved in dopamine synthesis. It may also modify pain sensitivity and persistence.
The GCH1 gene encodes a member of the GTP cyclohydrolase I family, and the protein is found in the cytoplasm and the nucleus. Several alternatively spliced transcript variants encode different isoforms, but not all give rise to a functional enzyme. Isoform GCH-1 is the functional enzyme, while the potential function of the enzymatically inactive isoforms remains unknown. This matters when selecting an GCH1 antibody or other detection reagent, since isoform coverage can differ between tools. Orthologues are annotated in mouse and rat as Gch1.
Mutations in the GCH1 gene are associated with malignant hyperphenylalaninemia and dopa-responsive dystonia. The latter is reflected in the aliases DYT5, DYT5a and the previous name dystonia 14 (DYT14). Because BH4 supply links amino acid metabolism, neurotransmitter synthesis and nitric oxide signalling, GCH1 is studied across neuroscience, vascular biology and pain research. GCHFR is a related target involved in regulating this enzyme.
GCH1 is the first and rate-limiting enzyme in BH4 synthesis, making it a key point for studying cofactor supply.
GCH1 may be involved in dopamine synthesis, and its mutations are associated with dopa-responsive dystonia.
GCH1 positively regulates nitric oxide synthesis in HUVECs, and BH4 is a cofactor for nitric oxide synthases.
GCH1 may modify pain sensitivity and persistence, giving a route into mechanisms of pain processing.
GCH1 is the first and rate-limiting enzyme in tetrahydrobiopterin (BH4) biosynthesis, converting GTP into 7,8-dihydroneopterin triphosphate. BH4 is a required cofactor for aromatic amino acid hydroxylases and nitric oxide synthases. GCH1 also positively regulates nitric oxide synthesis in HUVECs and may be involved in dopamine synthesis.
GCH1 is also called GTPCH1, GCH, DYT5, DYT5a and DYT14, and was previously named dystonia 14. Several splice variants encode different isoforms. Isoform GCH-1 is the functional enzyme, while the function of the enzymatically inactive isoforms remains unknown.
Mutations in GCH1 are associated with malignant hyperphenylalaninemia and dopa-responsive dystonia. Mouse and rat both carry a Gch1 orthologue, which supports use of rodent models. Check the datasheet of any product for its validated reactivity.
Regulatory partners of GTP cyclohydrolase 1 and other targets in tetrahydrobiopterin biosynthesis with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P30793; product specifications from Assay Genie datasheets.